Skip to main navigation
Plx Pharma logo

News Releases

Plx Pharma logo Plx Pharma logo Plx Pharma logo Plx Pharma logo
  • Home
  • About Us
    • About Us
    • Our Story
    • Management Team
    • Scientific Advisory Board
    • Board of Directors
  • Our Technology
    • Our Technology
    • VazaloreTM
    • Pipeline
    • Publications
  • Investors
  • FAQS
  • Contact
Plx Pharma logo Plx Pharma logo Plx Pharma logo Plx Pharma logo
  • Home
  • About Us
    • About Us
    • Our Story
    • Management Team
    • Scientific Advisory Board
    • Board of Directors
  • Our Technology
    • Our Technology
    • VazaloreTM
    • Pipeline
    • Publications
  • Investors
  • FAQS
  • Contact
Plx Pharma logo Plx Pharma logo Plx Pharma logo Plx Pharma logo
  • Home
  • About Us
    • About Us
    • Our Story
    • Management Team
    • Scientific Advisory Board
    • Board of Directors
  • Our Technology
    • Our Technology
    • VazaloreTM
    • Pipeline
    • Publications
  • Investors
  • FAQS
  • Contact
Plx Pharma logo Plx Pharma logo Plx Pharma logo Plx Pharma logo
  • Home
  • About Us
    • About Us
    • Our Story
    • Management Team
    • Scientific Advisory Board
    • Board of Directors
  • Our Technology
    • Our Technology
    • VazaloreTM
    • Pipeline
    • Publications
  • Investors
  • FAQS
  • Contact
Plx Pharma logo Plx Pharma logo Plx Pharma logo Plx Pharma logo
  • Home
  • About Us
    • About Us
    • Our Story
    • Management Team
    • Scientific Advisory Board
    • Board of Directors
  • Our Technology
    • Our Technology
    • VazaloreTM
    • Pipeline
    • Publications
  • Investors
  • FAQS
  • Contact
Plx Pharma logo Plx Pharma logo Plx Pharma logo Plx Pharma logo
  • Home
  • About Us
    • About Us
    • Our Story
    • Management Team
    • Scientific Advisory Board
    • Board of Directors
  • Our Technology
    • Our Technology
    • VazaloreTM
    • Pipeline
    • Publications
  • Investors
  • FAQS
  • Contact
  • Home
  • About Us
    • About Us
    • Our Story
    • Management Team
    • Scientific Advisory Board
    • Board of Directors
  • Our Technology
    • Our Technology
    • VazaloreTM
    • Pipeline
    • Publications
  • Investors
  • FAQS
  • Contact
Investor Menu
  • Overview
  • News Releases
  • Events & Presentations
    • Events
    • Presentations
  • Stock
    • Stock Quote & Chart
    • Historical Price Lookup
    • Analyst Coverage
  • Governance
    • Document & Charters
    • Committee Composition
  • Financials
    • SEC Filings
    • Financial Results
  • IR Resources
    • Investor FAQs
    • Email Alerts
    • Contact IR

News Releases

PLx Pharma Inc. Reports Third Quarter 2022 Results and Provides Business Update
- Significant Reduction in Operating Expenses - Strategic Alternatives Process Ongoing Total Net Sales of $0.4 Million , Including $0.3 Million of Unfavorable Adjustments for Additional Trade Allowances and Incremental Sales Returns Reserves in Q3 2022 Total Operating Expenses Significantly Lower
November 10, 2022
Read More
PLx Pharma Inc. to Report Third Quarter 2022 Financial Results on November 11, 2022, and Provide Business Update
SPARTA, N.J. , Oct. 26, 2022 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ: PLXP) (“PLx” or the “Company”) is a commercial-stage drug delivery platform technology company focused on its clinically-validated and patent-protected PLxGuard™ that has the potential to improve the absorption of many drugs
October 26, 2022
Read More
Baseball Legend John Smoltz Featured on PLx Pharma’s Social Channels
Legendary Baseball Pitcher and Avid Golfer Uses VAZALORE® 325 mg for Fast, Effective Pain Relief SPARTA, N.J. , Sept. 12, 2022 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ: PLXP) (“PLx” or the “Company”) is a commercial-stage drug delivery platform technology company focused on its
September 12, 2022
Read More
PLx Pharma Inc. Reports Second Quarter 2022 Results and Provides Business Update
- Initiates Evaluation of Strategic Alternatives to Enhance Stockholder Value - Reports Positive Results of VAZALORE ® 81 mg Patient Experience Survey - Streamlines Sales & Marketing Plan Total Net Sales of $0.5 Million , Including $0.4 Million of Unfavorable Adjustments for Additional Trade
August 12, 2022
Read More
PLx Pharma Inc. to Report Second Quarter 2022 Financial Results August 12, 2022, and Provide Business Update
SPARTA, N.J. , July 27, 2022 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ: PLXP) (“PLx” or the “Company”) is a commercial-stage drug delivery platform technology company focused on its clinically-validated and patent-protected PLxGuard™ that has the potential to improve the absorption of many drugs
July 27, 2022
Read More
PLx Pharma Inc. to Present at JMP Securities 2022 Life Sciences Conference on June 15, 2022
SPARTA, N.J. , June 01, 2022 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ: PLXP) (“PLx” or the “Company”) is a commercial-stage drug delivery platform technology company focused on its clinically-validated and patent-protected PLxGuard™ that has the potential to improve the absorption of many drugs
June 1, 2022
Read More
PLx Pharma Inc. Showcases VAZALORE at The Annual Meeting of The Society for Cardiovascular Angiography and Interventions
VAZALORE Featured in Prominent Publication as Promising Alternative to Current Aspirin Options for Secondary Prevention of Cardiac Events SPARTA, N. J., May 20, 2022 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ: PLXP) (“PLx” or the “Company”), is a commercial-stage drug delivery platform technology
May 20, 2022
Read More
PLx Pharma Inc. Reports First Quarter 2022 Results and Provides Business Update
BUILDING A SOLID BASE OF VAZALORE ® USERS Total Net Sales of $2.1 Million in the First Quarter of 2022, an Increase of Approximately 31% from Fourth Quarter of 2021 GAAP Net Loss of ( $0.39 ) Per Diluted Share in the First Quarter 2022; Adjusted Non-GAAP Net Loss Per Diluted Share of ( $0.66 ) Cash
May 13, 2022
Read More
PLx Pharma Inc. to Discuss 2022 First Quarter Financial Results on May 13, 2022 Conference Call and Provide Business Update
SPARTA, N.J. , April 22, 2022 (GLOBE NEWSWIRE) -- PLx Pharma Inc.  (NASDAQ: PLXP) (“PLx” or the “Company”) is a commercial-stage drug delivery platform technology company focused on its clinically-validated and patent-protected PLxGuard™ that has the potential to improve the absorption of many
April 22, 2022
Read More
PLx Pharma Inc. Reports Fourth Quarter and Full Year 2021 Results and Provides Business Update
Momentum Building for Novel Vazalore ® Liquid-Filled Aspirin Capsules Total Net Sales of $8.2 Million in Last Five Months of 2021 Net Sales of $1.6 Million in the Fourth Quarter 2021, Reflecting Timing of Trade Re-Orders Following Strong Initial Sales Distribution of VAZALORE in the Third Quarter
March 11, 2022
Read More

Pagination

  • Current page 1
  • Page 2
  • Next page next ›
  • Last page last »
Displaying 1 - 10 of 14
  • Print Page
  • RSS Feeds
  • Email Alerts
Plx Pharma logo

Quick Links

  • Privacy Policy
  • Terms and Conditions
  • Site Map
  • Contact Us

Contacts

  • info@plxpharma.com
  • (973) 409-6541
  • (973) 843-6300
  • 9 Fishers Lane, Suite E
    Sparta, NJ 07871

© 2023 PLx Pharma Inc. All rights reserved.